INTRODUCTION AND OBJECTIVES: Bladder Pain Syndrome/ Interstitial Cystitis (BPS/IC) is a disease that causes pelvic pain and lower urinary tract symptoms. Psychological stress has been proposed as a factor inducing or worsening BPS/IC symptoms. Accordingly, an animal model of psychological stress induced by water avoidance stress (WAS), which exhibits pelvic pain and urinary frequency, has been proposed as a useful model to study the BPS/IC pathophysiology. Previous studies have also shown that nerve growth factor (NGF) that is known to cause sensitization of nociceptive afferent pathways is increased in the bladder of BPS/IC patients and that urothelial intercellular distance in WAS rats is increased. Thus, in this study using WAS rats, we examined bladder function, pain sensation and expressions of NGF, junction molecules and TRP channels in bladder mucosa.
INTRODUCTION AND OBJECTIVES: Bladder Pain Syndrome/ Interstitial Cystitis (BPS/IC) is a disease that causes pelvic pain and lower urinary tract symptoms. Psychological stress has been proposed as a factor inducing or worsening BPS/IC symptoms. Accordingly, an animal model of psychological stress induced by water avoidance stress (WAS), which exhibits pelvic pain and urinary frequency, has been proposed as a useful model to study the BPS/IC pathophysiology. Previous studies have also shown that nerve growth factor (NGF) that is known to cause sensitization of nociceptive afferent pathways is increased in the bladder of BPS/IC patients and that urothelial intercellular distance in WAS rats is increased. Thus, in this study using WAS rats, we examined bladder function, pain sensation and expressions of NGF, junction molecules and TRP channels in bladder mucosa.
METHODS: Female Wistar rats were divided into the WAS group, which underwent 1-hour WAS for 10 days, and the control group without WAS. All rats then underwent cystometry with intravesical infusion of low dose protamine sulfate (LD-PS) (10mg/ml), which reportedly does not cause changes in bladder activity in normal rats. In separate groups of WAS or control rats, bladder pain behavior after intravesical infusion of LD-PS was evaluated. After the experiments, bladder tissues were harvested for RT-PCR and ELISA analyses. Bladder sections were also evaluated histologically to see the degree of damage caused by PS.
RESULTS: Control rats did not show changes in intercontraction intervals (ICI) whereas WAS rats showed a significant decrease of ICI after LD-PS infusion (Fig: A) . WAS rats also showed a significant increase in PS-induced bladder pain behaviors compared to controls (Fig: B) . In bladder mucosa of WAS rats, NGF protein and TRPV1/TRPA1 mRNA levels were increased whereas mRNA levels of junction molecules (Cx43, ZO-1) were decreased (Fig: C&D) . Histological evaluation showed the bladder epithelial damage with LD-PS in WAS rats, but not in control rats.
CONCLUSIONS: Psychological stress due to WAS increased urinary frequency and bladder pain sensation after LD-PS infusion. WAS-induced NGF upregulation and decreases of junction molecules in bladder mucosa may contribute to the increased susceptibility to bladder insults leading to the urothelial damage.
Source of Funding: none

MP47-15 GENE EXPRESSION PROFILES OF BLADDER MUSCOSA STRATIFIES IC/BPS PATIENTS BASED ON ANESTHETIZED BLADDER CAPACITY
Stephen Walker*, Jeffrey Schachar, Gopal Badlani, Catherine Matthews, Joao Zambon, Robert Evans, Winston Salem, NC INTRODUCTION AND OBJECTIVES: The goal of this study was to further explore our working hypothesis that the low capacity bladder mucosal gene expression profile is representative of a bladdercentric interstitial cystitis/bladder pain syndrome (IC/BPS) subphenotype. This hypothesis is based on data from our earlier pilot study showing that a subset of IC/BPS patients (those with a severely diminished bladder capacity [BC; 400 ml]) displayed a unique gene expression profile.
METHODS: IC/BPS patient biopsy samples (N[40) were selected from our tissue bank (IRB00018552) for gene expression profiling. Specimens were chosen based on anesthetic bladder capacity (BC) ranging from 200-1500ml to provide a representative sample of the entire cohort. Thirteen samples came from patients that we define as 'low' BC ( 400 ml; 7/13 were Hunner's lesion positive [HLþ] ) and 27 were from patients with a BC >400 ml (1/27 was HLþ). All patients had undergone therapeutic bladder hydrodistention per the AUA guideline algorithm. Total RNA was isolated from mucosal biopsies (per standard protocols) and assayed on whole genome microarrays (Illumina HT v4 BeadArray). Hierarchical clustering was used to identify similar groups of samples on the basis of their gene expression profile.
RESULTS: Bladder capacity accounted for approximately 60% of the overall variation in mucosal gene expression among all samples. Hierarchical clustering revealed two primary clusters (Figure 1 ). Cluster A consisted exclusively of samples from the BC >400ml group (heatmap; Figure 1 , right side). Cluster B contained all samples with BC 400 ml (Figure 1, left side) . Within Cluster B there are 2 subgroups: one consisting largely of low BC /HLþ samples; the other consisting largely of those with low BC/HL-. Four of the 5 samples that were not in the 'low' BC group and yet clustered within the 'low' BC/HL-subgroup had diminished BC (either 450 or 500 ml).
CONCLUSIONS: Gene expression in mucosal biopsy tissue from IC/BPS patients provides a degree of stratification when correlated with anesthetic bladder capacity. These pilot data reveal three distinct IC/BPS subgroups and information mined from differentially-expressed genes between each subgroup may provide further insight into the heterogeneity seen in IC/BPS.
Source of Funding: NIH NIDDK R01 (SJW)
MP47-16 PUDENDAL NEUROMODULATION FOR PELVIC PAIN: OPTIMIZING PATIENT SELECTION
Iryna Crescenze, Giulia Lane*, Priyanka Gupta, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: Pudendal neuralgia is characterized by pelvic pain in the pudendal nerve distribution that exacerbated by sitting, improved with pudendal nerve blocks, and may have concomitant bladder and bowel symptoms. There is lack of evidence based treatment options for this condition but recent studies have proposed the utility of pudendal neuromodulation in this population. The aim of this study was to optimize patient selection for pudendal neuromodulation to improve overall outcomes.
METHODS: Patients undergoing pudendal neuromodulation for indication of refractory pelvic pain and voiding dysfunction from 8/1/ 2016 to 8/1/2018 at a single institution were identified through retrospective review of electronic medical records. Clinical, demographic, and outcome data was extracted and analyzed. Patients undergoing pudendal neuromodulation for voiding symptoms only were excluded. Prior to proceeding with pudendal neuromodulation diagnoses of pudendal neuralgia was confirmed by assessing for consistent improvement with pudendal blocks. All patients had at least 2 blocks. All patients underwent staged implantation.
RESULTS: Ten patients with chronic pelvic pain and overactive bladder symptoms had a staged trial of pudendal neuromodulation. All patients were women with an average age of 55.4AE9.7 years and an average duration of symptoms was 6.6 AE 5.19 years. Sixty percent suffered from depression, 40% had fibromyalgia, and 100% had bowel dysfunction (constipation and/or fecal incontinence). All patient had tried and failed multiple medications and pelvic floor physical therapy. All patients had a positive response to pudendal blocks with 80% having at least 4 blocks. Of the 10 patients, 9 had a successful stage I trial with >50% improvement in pain symptoms and proceeded to stage II.
At first follow up AUA symptom scores improved from 14.1AE9.44 to 5.7AE2.0 (p[0.037), and quality of life from 4.0AE1.5 to 1.6AE2.1(p[0.026). At an average of 8.1AE 4.9 months of follow up 7/9 were satisfied with the outcomes. Of the 2 patients dissatisfied one went on to have a cystectomy and one had the device removed.
CONCLUSIONS: Consistent positive response to pudendal nerve blocks translates to excellent response rates to pudendal neuromodulation with a 90% conversion rate to permanent implant for indication of pain. This cohort also experienced significant improvement in voiding symptoms with continued efficacy during the follow-up period. METHODS: This prospective case-controlled study compared the voided FUM in women with symptoms of urinary frequency, urgency, and bladder pain for greater than 6 months meeting AUA IC/ PBS definition. Bacterial identification was performed using 16S rRNA gene sequencing and EQUC, a validated enhanced urine culture approach. Urotypes were defined as genera present at >50% relative abundance. If no genera were present at this threshold, the urotype was classified as 'mixed'. Chi-square and Fisher's exact tests were performed. P-values <0.05 were considered significant. RESULTS: A mid-stream voided specimen was collected from 21 IC/PBS patients and 20 asymptomatic controls. The two groups had similar demographics and clinical characteristics (p>0.05 for all comparisons). Urotypes did not differ between cohorts as assessed by EQUC or 16S sequencing. We also detected no significant differences in any measure of alpha-diversity. By EQUC, there were some differences in community structure. Group B Streptococcus (p[0.045) CONCLUSIONS: Ours is the first study using modern culture and DNA sequencing methods to suggest that IC/PBS symptoms may not be related to differences in the FUM, at least not its bacterial components. Future larger studies are needed to confirm this preliminary finding.
Source of
